194 related articles for article (PubMed ID: 7997072)
21. M1 muscarinic acetylcholine receptors: A therapeutic strategy for symptomatic and disease-modifying effects in Alzheimer's disease?
Scarpa M; Hesse S; Bradley SJ
Adv Pharmacol; 2020; 88():277-310. PubMed ID: 32416870
[TBL] [Abstract][Full Text] [Related]
22. Activation of muscarinic acetylcholine receptors via their allosteric binding sites.
Jakubík J; Bacáková L; Lisá V; el-Fakahany EE; Tucek S
Proc Natl Acad Sci U S A; 1996 Aug; 93(16):8705-9. PubMed ID: 8710935
[TBL] [Abstract][Full Text] [Related]
23. Differential regulation of molecular subtypes of muscarinic receptors in Alzheimer's disease.
Flynn DD; Ferrari-DiLeo G; Mash DC; Levey AI
J Neurochem; 1995 Apr; 64(4):1888-91. PubMed ID: 7891119
[TBL] [Abstract][Full Text] [Related]
24. Targeting Muscarinic Acetylcholine Receptors for the Treatment of Psychiatric and Neurological Disorders.
Moran SP; Maksymetz J; Conn PJ
Trends Pharmacol Sci; 2019 Dec; 40(12):1006-1020. PubMed ID: 31711626
[TBL] [Abstract][Full Text] [Related]
25. Potential role of muscarinic agonists in Alzheimer's disease.
Avery EE; Baker LD; Asthana S
Drugs Aging; 1997 Dec; 11(6):450-9. PubMed ID: 9413702
[TBL] [Abstract][Full Text] [Related]
26. The Muscarinic Acetylcholine Receptor M
Bender AM; Garrison AT; Lindsley CW
ACS Chem Neurosci; 2019 Mar; 10(3):1025-1034. PubMed ID: 30280567
[TBL] [Abstract][Full Text] [Related]
27. Crystal structures of the M1 and M4 muscarinic acetylcholine receptors.
Thal DM; Sun B; Feng D; Nawaratne V; Leach K; Felder CC; Bures MG; Evans DA; Weis WI; Bachhawat P; Kobilka TS; Sexton PM; Kobilka BK; Christopoulos A
Nature; 2016 Mar; 531(7594):335-40. PubMed ID: 26958838
[TBL] [Abstract][Full Text] [Related]
28. M1 muscarinic agonists as potential disease-modifying agents in Alzheimer's disease. Rationale and perspectives.
Fisher A; Michaelson DM; Brandeis R; Haring R; Chapman S; Pittel Z
Ann N Y Acad Sci; 2000; 920():315-20. PubMed ID: 11193170
[TBL] [Abstract][Full Text] [Related]
29. Allosteric activators of muscarinic receptors as novel approaches for treatment of CNS disorders.
Digby GJ; Shirey JK; Conn PJ
Mol Biosyst; 2010 Aug; 6(8):1345-54. PubMed ID: 20582339
[TBL] [Abstract][Full Text] [Related]
30. Selective activation of muscarinic acetylcholine receptors for the treatment of schizophrenia.
Dean B
Curr Pharm Biotechnol; 2012 Jun; 13(8):1563-71. PubMed ID: 22283751
[TBL] [Abstract][Full Text] [Related]
31. Allosteric effects of four stereoisomers of a fused indole ring system with 3H-N-methylscopolamine and acetylcholine at M1-M4 muscarinic receptors.
Lazareno S; Birdsall B; Fukazawa T; Gharagozloo P; Hashimoto T; Kuwano H; Popham A; Sugimoto M; Birdsall NJ
Life Sci; 1999; 64(6-7):519-26. PubMed ID: 10069518
[TBL] [Abstract][Full Text] [Related]
32. Subtype selectivity of the positive allosteric action of alcuronium at cloned M1-M5 muscarinic acetylcholine receptors.
Jakubík J; Bacáková L; el-Fakahany EE; Tucek S
J Pharmacol Exp Ther; 1995 Sep; 274(3):1077-83. PubMed ID: 7562472
[TBL] [Abstract][Full Text] [Related]
33. The potential for muscarinic receptor subtype-specific pharmacotherapy for Alzheimer's disease.
McKinney M; Coyle JT
Mayo Clin Proc; 1991 Dec; 66(12):1225-37. PubMed ID: 1749291
[TBL] [Abstract][Full Text] [Related]
34. SAR studies on carboxylic acid series M(1) selective positive allosteric modulators (PAMs).
Kuduk SD; Beshore DC
Curr Top Med Chem; 2014; 14(15):1738-54. PubMed ID: 25176125
[TBL] [Abstract][Full Text] [Related]
35. Current status of muscarinic M1 and M4 receptors as drug targets for neurodegenerative diseases.
Felder CC; Goldsmith PJ; Jackson K; Sanger HE; Evans DA; Mogg AJ; Broad LM
Neuropharmacology; 2018 Jul; 136(Pt C):449-458. PubMed ID: 29374561
[TBL] [Abstract][Full Text] [Related]
36. AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer's disease.
Fisher A; Brandeis R; Bar-Ner RH; Kliger-Spatz M; Natan N; Sonego H; Marcovitch I; Pittel Z
J Mol Neurosci; 2002; 19(1-2):145-53. PubMed ID: 12212772
[TBL] [Abstract][Full Text] [Related]
37. Allosteric modulators and selective agonists of muscarinic receptors.
Holzgrabe U; De Amici M; Mohr K
J Mol Neurosci; 2006; 30(1-2):165-8. PubMed ID: 17192667
[TBL] [Abstract][Full Text] [Related]
38. Effects of central muscarinic-1 receptor stimulation on blood pressure regulation.
Medina A; Bodick N; Goldberger AL; Mac Mahon M; Lipsitz LA
Hypertension; 1997 Mar; 29(3):828-34. PubMed ID: 9052903
[TBL] [Abstract][Full Text] [Related]
39. M1 muscarinic allosteric modulators slow prion neurodegeneration and restore memory loss.
Bradley SJ; Bourgognon JM; Sanger HE; Verity N; Mogg AJ; White DJ; Butcher AJ; Moreno JA; Molloy C; Macedo-Hatch T; Edwards JM; Wess J; Pawlak R; Read DJ; Sexton PM; Broad LM; Steinert JR; Mallucci GR; Christopoulos A; Felder CC; Tobin AB
J Clin Invest; 2017 Feb; 127(2):487-499. PubMed ID: 27991860
[TBL] [Abstract][Full Text] [Related]
40. Pharmacological approaches to targeting muscarinic acetylcholine receptors.
Matera C; Tata AM
Recent Pat CNS Drug Discov; 2014; 9(2):85-100. PubMed ID: 25413004
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
